MTSS (Myelofibrosis Transplant Scoring System) Calculator
Use this tool to estimate a transplant-risk category for myelofibrosis based on commonly used MTSS-style clinical variables.
Educational use only. This calculator is not a substitute for specialist medical judgment, institutional protocols, or shared decision-making with a hematology/transplant team.
What is the MTSS score in myelofibrosis?
The MTSS score (Myelofibrosis Transplant Scoring System) is a transplant-focused risk framework used in patients with myelofibrosis who are being evaluated for allogeneic stem cell transplantation. Unlike general prognosis models, MTSS is designed to estimate risk around transplant outcomes using patient, disease, and donor-related features.
Because transplant is the only potentially curative option for many patients with myelofibrosis, having a structured way to discuss risk can help patients and clinicians compare timing, donor strategy, and supportive planning.
How this calculator works
This page calculates an MTSS-style point total using practical clinical factors that are commonly associated with transplant risk:
- Age
- Karnofsky performance status
- Platelet count
- Leukocyte (white blood cell) count
- ASXL1 mutation status
- Driver mutation category
- Transfusion dependence
- Donor matching category
After calculation, the tool returns a risk group (low, intermediate, high, very high) and highlights which inputs added risk points. This supports transparent discussion and allows quick scenario testing—for example, how risk profile changes with donor choice.
Interpreting your result
Low risk
Typically indicates a more favorable transplant-risk profile. This does not mean “no risk,” but may suggest better expected tolerance and outcomes compared with higher groups.
Intermediate risk
Represents moderate risk where disease factors and patient fitness should be reviewed carefully. This is often where individualized planning has major impact.
High risk
Indicates substantial risk burden. Teams may focus on optimization before transplant, detailed donor strategy, and close peri-transplant monitoring.
Very high risk
Suggests significant adverse factors. In practice, these patients require nuanced multidisciplinary review, including reassessment of timing, center expertise, supportive care strategy, and patient goals.
Why transplant-specific scoring matters
Myelofibrosis prognosis can be assessed with several systems (for example, DIPSS and molecularly informed tools), but transplant decisions include additional layers:
- Donor compatibility and graft considerations
- Functional status and physiologic reserve
- Mutation profile and disease biology
- Blood count trends and transfusion burden
MTSS-style models help capture this transplant context and improve risk communication between clinicians and patients.
Important limitations
- This calculator provides an educational estimate, not a definitive clinical prediction.
- Center-specific protocols, conditioning regimen, and supportive care can alter outcomes significantly.
- Mutation reporting may vary by panel and laboratory standards.
- Real-world decisions should integrate comorbidities, frailty, patient priorities, and evolving treatment options.
Practical next steps after using the calculator
- Bring your calculated score to your hematologist/transplant consultation.
- Ask how your institution defines donor-related risk categories.
- Review whether your molecular panel is complete and current.
- Discuss pre-transplant optimization: nutrition, functional conditioning, infection prevention, and transfusion planning.
- Clarify your goals of care and acceptable risk thresholds.
FAQ: mtss score myelofibrosis calculator
Is this an official medical device?
No. It is an educational web calculator intended to support understanding and discussion.
Can this replace a transplant consultation?
No. A full consultation includes physical assessment, lab review, imaging, genetics, and center-level expertise that cannot be fully captured by a simple web form.
Should I delay treatment based on this number alone?
No. Treatment timing should never rely on one score in isolation. Use this result only as one component of a broader clinical conversation.